Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Analyse des nouvelles recommandations européennes dans l’hypertension artérielle


The new European Guidelines in Hypertension: Critical Analysis

Updated guidelines for the management of arterial hypertension have recently been published by the American Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the European Society of Hypertension and European Society of Cardiology. Although there are several similarities between the American and the European guidelines, there are nevertheless some fundamental differences as well.


Des recommandations réactualisées sur la prise en charge de l’hypertension artérielle ont été récemment publiées par le Comité paritaire des Etats-Unis sur la prévention, le dépistage, l’évaluation et le traitement de l’hypertension artérielle et les Sociétés Européennes d’Hypertension artérielle et de Cardiologie. Bien qu’il existe plusieurs points communs entre les recommandations américaines et européennes, il existe également quelques différences fondamentales.

This is a preview of subscription content, log in to check access.

Tableau I
Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Guidelines Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

  2. 2.

    Guidelines Sub-Committee. 1999 World Health Organisation-International Society of Hypertension Guidelines for the management of hypertension. Blood Pressure 1999; 8 (Suppl 1): 3–5

  3. 3.

    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–72

  4. 4.

    Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13

  5. 5.

    Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency and progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682–6

  6. 6.

    Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7

  7. 7.

    Conroy RM, Pyörälä K, Fitzgerald AP, et al, on behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003

  8. 8.

    Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–8

  9. 9.

    Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461–4

  10. 10.

    Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362; 1527–35

  11. 11.

    Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76

  12. 12.

    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97

Download references

Author information

Correspondence to Professor Giuseppe Mancia.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mancia, G. Analyse des nouvelles recommandations européennes dans l’hypertension artérielle. Am J Cardiovasc Drugs 4, 1–6 (2004).

Download citation